1. Rolston KVI, Bodey GP (2006) Infections in patients with cancer. In: Kufe DW, Bast RC Jr, Hait WN, Hong WK, Pollock RE, Weichselbaum RR, Holland JF, Frei E III (eds) Cancer Medicine, e7. BC Decker, Hamilton, Ontario, pp 2222–2245
2. Hughes WT, Armstrong D, Bodey GP et al (2002) 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751
3. Talcott JA, Siegel RD, Finberg R et al (1992) Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 10:316–322
4. Klastersky J, Paesmans M, Rubenstein E et al (2000) The MASCC Risk Index: A multinational scoring system to predict low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051
5. Rolston K (1999) New trends in patient management: Risk-based therapy for febrile patients with neutropenia. Clin Infect Dis 29:515–521